US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead Exton, Pennsylvania, Oct. 13, 2023 (GLOBE NEWSWIRE) -- The FDA's recent approvals of Calliditas' Tarpeyo (budesonide) and Travere's Filspari (sparsentan) to treat primary IgA nephropathy (IgAN) have...

Diabetic Nephropathy Market Size Expected to Reach USD 3.34 Billion by 2028, at a 4.3% CAGR Pune, India, March 09, 2023 (GLOBE NEWSWIRE) -- The global diabetic nephropathy market size was valued at USD 2.38 billion in 2020. The market is estimated to rise from USD 2.49 billion in 2021 to...

Diabetic Nephropathy Market Size Worth USD 3.43 Billion by 2030 at 6.20% CAGR – Report by Market Research Future (MRFR) New York, USA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Diabetic Nephropathy Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), The Diabetic Nephropathy...

Diabetic Nephropathy Disease Analysis Report 2021: Overall Likelihood of Approval of a Phase I DN Asset is 4%, and the Average Probability a Drug Advances from Phase III is 33.3% Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Diabetic Nephropathy" report has been added to ResearchAndMarkets.com's offering. Diabetic nephropathy, also known as diabetic...

Reaching underserved patients in the kidney community: American Kidney Fund expands online resources for rare diseases ROCKVILLE, Md., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Because many relatively unknown rare diseases can cause permanent damage to the kidneys, the American Kidney Fund (AKF) today announced it has...